Quratis Inc.
KKRX:3480803,330.00
KRW
-20.00
(-0.60%)
ISIN
KR7348080003
Return %
Stock
S&P 500
1Y
-59.83
14.39
3Y
-87.63
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Seong Kim
- Full Time Employees
- 47
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Cheongju-si South Korea
- IPO Date
- Jun 15, 2023
- Website
- quratis.com
- Similar Companies
- Business
- Quratis Inc. is a South Korea-based clinical-stage biotechnology company engaged in the research, development, and commercial manufacturing of vaccines and immunotherapies for infectious diseases and immune disorders, as well as the provision of biopharmaceutical contract development and manufacturing organization (CDMO) services. The company's core product pipeline and service offerings include QTP101, a recombinant protein subunit vaccine candidate formulated with an adjuvant system for adolescent and adult tuberculosis; QTP104, a next-generation self-amplifying messenger RNA (saRNA) vaccine candidate targeting respiratory viruses; peptide-based immunotherapeutics for specialized immune and infectious indications; and end-to-end CDMO and contract manufacturing services encompassing microbial fermentation, mRNA synthesis, lipid nanoparticle (LNP) encapsulation, formulation development, and automated aseptic fill-finish operations for liquid and lyophilized vial injectables. Quratis operates primarily within South Korea while advancing international clinical development and commercialization partnerships across the Asia-Pacific region, including Indonesia and the Philippines. Founded in 2016, the company is headquartered in Seoul, South Korea, and operates its cGMP-compliant manufacturing and research facility in Osong, Chungcheongbuk-do. In recent developments, Quratis completed its public listing on the KOSDAQ market (KRX:348080); secured multi-regional clinical trial authorizations and distribution partnerships across Southeast Asia for its QTP101 tuberculosis vaccine candidate; expanded its commercial CDMO services for third-party biopharmaceutical developers; and executed corporate financing initiatives to advance late-stage clinical development and optimize production capacity at its Osong Bio Plant.